Tetragon Partners GP Ltd — ARROWHEAD PHARMACEUTICALS INC ARWR: Quarterly 13F Position History
Tetragon Partners GP Ltd has reported ARROWHEAD PHARMACEUTICALS INC (ARWR) on 3 13F-HR filings in Pactolio's tracked window, first appearing in Q3 2025. As of Q1 2026, the position is sized at 127,198 shares ($8.0M market value, 1.57% of the equity book). Quarter-over-quarter share count change: + 30,263 (+31.2%) .
- 127,198Shares Held (Latest Filing)
- $8.0MReported Market Value (Latest Filing)
- 1.57%Portfolio Weight (% of 13F Equity Book)
- +30,263Quarter-over-Quarter Share Change
- +$1.5MQuarter-over-Quarter Value Change
- 127,198Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 3 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 127,198 | +30,263 | +31.2% | $8.0M | 1.57% | $62.70 |
| Q4 2025 | 96,935 | +15,094 | +18.4% | $6.4M | 1.36% | $66.39 |
| Q3 2025 | 81,841 | — | — | $2.8M | 0.41% | $34.49 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Tetragon Partners GP Ltd first disclose a ARWR position in 13F-HR filings?
Tetragon Partners GP Ltd first reported ARROWHEAD PHARMACEUTICALS INC (ARWR) on its 13F-HR filing for the period ending 2025-09-30 (Q3 2025). The position has appeared on 3 reported quarters within Pactolio's tracked window.
What was Tetragon Partners GP Ltd's most recent quarter-over-quarter share-count change in ARWR?
Between Q4 2025 and Q1 2026, Tetragon Partners GP Ltd added 30,263 shares of ARWR (+31.2%), bringing the total reported position to 127,198 shares at a market value of $8.0M.
Does the implied price-per-share represent Tetragon Partners GP Ltd's cost basis in ARWR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.